Skip to main content

Table 3 In vitro susceptibility of oral isolates to fluconazole and itraconazole as related to previous antifungal therapy

From: Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis

Antifungal Previous antifungal (n = 176a) No previous antifungal (n = 128b) P-value
  S SDD R S SDD R  
Fluconazole 149 (84.7) 17 (9.7) 10 (5.7) 112 (93.3) 3 (2.5) 5 (4.2) 0.037
Itraconazole 133 (75.6) 22 (12.5) 21 (11.9) 112 (93.3) 4 (3.3) 4 (3.3) 0.002
  1. Data are expressed as number of isolates (percentage).
  2. S – Susceptible, SDD – Susceptible dose dependent, R – resistant.
  3. Interpretive breakpoint criteria of the CLSI (2002): Fluconazole; S (MIC ≤ 8 μg/ml), SDD (MIC 16 – 32 μg/ml), R (MIC 64 μg/ml) and Itraconazole; S (MIC ≤ 0.125 μg/ml), SDD (MIC 0.25 – 0.5 μg/ml), R (MIC ≥ 1).
  4. aC. albicans (143), C. glabrata (19), C. tropicalis (4), S. cerevisiae (2), C. pintolopesii (1).
  5. bC. albicans (107), C. glabrata (1), C. tropicalis (4), C. kefyr (3), S. cerevisiae (1), C. dubliniensis (1).